Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR52M1 Inhibitors

OR52M1 inhibitors represent a distinct class of chemical compounds designed to specifically target the OR52M1 receptor, a member of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. While olfactory receptors like OR52M1 are primarily associated with the detection of odor molecules, they are also expressed in various non-olfactory tissues, indicating potential roles beyond the sensory perception of smell. Inhibitors of OR52M1 are crafted to interact with this receptor in a way that modulates its activity, often by blocking the receptor's ability to bind to its natural ligands. By preventing this binding, OR52M1 inhibitors can alter the receptor's signaling pathways, thereby influencing the biological processes in which OR52M1 is involved. The study and development of these inhibitors are important for understanding the diverse roles of OR52M1, particularly in non-olfactory systems where its function is not fully elucidated. The chemical nature of OR52M1 inhibitors can vary widely, with different compounds exhibiting different mechanisms of action. Some inhibitors may act as competitive antagonists, binding to the same site on OR52M1 as its natural ligands and effectively blocking these ligands from activating the receptor. Others may act as non-competitive or allosteric inhibitors, binding to different sites on the receptor and inducing conformational changes that reduce its activity. The design of OR52M1 inhibitors typically involves the use of advanced structural biology techniques, such as X-ray crystallography, cryo-electron microscopy, and molecular modeling, to identify the key binding sites on the receptor and optimize the interactions between the inhibitor and OR52M1. These studies aim to enhance the potency, specificity, and selectivity of the inhibitors, ensuring that they effectively target OR52M1 without affecting other receptors or proteins. Research into OR52M1 inhibitors is crucial for uncovering the molecular mechanisms underlying OR52M1's function and for exploring the broader implications of modulating this receptor's activity in various biological contexts.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$152.00
$479.00
$632.00
$1223.00
$2132.00
33
(3)

Trichostatin A may halt the deacetylation of histone proteins, leading to a hyperacetylated chromatin state that could constrain the transcription machinery's access to the OR52M1 gene, resulting in decreased expression.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

By inhibiting DNA methyltransferase, 5-Azacytidine could lead to hypomethylation of the OR52M1 gene promoter. This change may downregulate transcriptional initiation, thereby reducing the gene's expression levels.

Mithramycin A

18378-89-7sc-200909
1 mg
$55.00
6
(1)

Mithramycin A binds selectively to GC-rich DNA sequences, which may obstruct transcription factor binding sites on the OR52M1 gene promoter, leading to a decrease in OR52M1 transcriptional activity.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin (Sirolimus) may suppress mTOR pathway signaling, which is crucial for cap-dependent translation initiation. This suppression could contribute to a reduction in the synthesis of the OR52M1 protein.

Chloroquine

54-05-7sc-507304
250 mg
$69.00
2
(0)

Chloroquine′s interference with endosomal and lysosomal acidification could disrupt cellular signaling cascades that are essential for the transcriptional activation of the OR52M1 gene, thereby reducing its expression.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$66.00
$325.00
$587.00
$1018.00
28
(1)

Retinoic acid binds to its nuclear receptors, which may lead to altered expression of genes, including OR52M1. If retinoic acid disrupts transcriptional enhancers of OR52M1, it could result in its decreased expression.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$90.00
$204.00
13
(1)

Triptolide may inhibit the activity of RNA polymerase II, a critical enzyme for mRNA synthesis. This inhibition could directly lead to a decrease in the transcription levels of the OR52M1 gene.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$74.00
$243.00
$731.00
$2572.00
$21848.00
53
(3)

Actinomycin D may intercalate into DNA, thereby obstructing the elongation phase of RNA polymerase during mRNA synthesis. This blockage could result in reduced levels of OR52M1 mRNA.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD 98059 may inhibit MEK1/2 enzymes, which are part of the MAPK/ERK pathway. Inhibition of this pathway could lead to the downregulation of transcription factors that promote OR52M1 expression.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY 294002 may inhibit the PI3K/Akt signaling pathway, which could lead to a decrease in transcription factors or coactivators necessary for the expression of the OR52M1 gene, resulting in its lower expression levels.